TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07184827: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of U101 Oral Capsules in the Prevention of Uncomplicated Recurrent Urinary Tract Infections (rUTIs) in Women

Sponsor: TCM Biotech International Corp. · Phase: PHASE3 · Area: INFECTIOUS_VACCINE · Target Enrollment: 348 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$8,683,584

Rescue Site Savings

+$5,719,476

Unlock Full NCT07184827 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07184827 Rescue Dossier →